Vienna - Delayed Quote EUR

UCB SA (UCB.VI)

145.60

-0.45

(-0.31%)

As of 3:30:16 PM GMT+2. Market Open.

UCB presents latest research across leading neurology portfolio at American Academy of Neurology (AAN) meeting 2025

UCB, a global biopharmaceutical company, today announced it will present 24 abstracts from its expansive neurology portfolio, regarding rare epilepsies Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS), generalized myasthenia gravis (gMG), and thymidine kinase 2 deficiency (TK2d), at this year's American Academy of Neurology (AAN) meeting, San Diego, California, April 5-9, 2025.

PR Newswire 21 days ago

UCBJF

UCBJY
UCB Convening Notice to the General Meeting of the Shareholders 2025

CONVENING NOTICE TO THE GENERAL MEETING OF SHAREHOLDERS The Board of Directors invites the shareholders to the ordinary general meeting of the shareholders (the “General Meeting”) which will be held on Thursday, 24 April 2025, at 11:00 am CEST, at the registered office of UCB SA/NV, Allée de la Recherche 60 - 1070 Brussels, for the purpose of considering and voting on the items shown on the agenda set out below. Applicable participation formalities are detailed at the end of this convening notic

GlobeNewswire last month

UCBJF

UCBJY
New data on investigational therapy for thymidine kinase 2 deficiency presented at Muscular Dystrophy Association (MDA) 2025 Conference

UCB, a global biopharmaceutical company, today announced positive data from studies involving its investigational pyrimidine nucleoside therapy, doxecitine (dC) and doxribtimine (dT), in people living with thymidine kinase 2 deficiency (TK2d), at this year's MDA Clinical and Scientific Conference, Dallas, Texas, March 16-19, 2025.

PR Newswire last month

UCBJF

UCBJY
Epilepsia Publishes Final Analysis of Open-Label Extension Study of Long-Term Safety and Effectiveness of FINTEPLA® (fenfluramine) in Children and Adults with Dravet Syndrome

UCB, a global biopharmaceutical company, today announced that Epilepsia published findings from the final analysis of the long-term open-label extension (OLE) study evaluating the safety and effectiveness of FINTEPLA® (fenfluramine) in patients with Dravet syndrome (DS). Results showed that FINTEPLA was generally well tolerated. The most common treatment-emergent adverse events (TEAEs) were pyrexia, nasopharyngitis and decreased appetite.2 The efficacy analysis showed a statistically significant

PR Newswire last month

UCBJF

UCBJY
Europe-Based UCB's Bimzelx Data Reveals Sustained Skin Clearance In Inflammatory Skin Disorders

On Friday, UCB SA (OTC:UCBJY) (OTC:UCBJF) announced further long-term data from the Phase 3 trials and their open-label extensions, investigating Bimzelx (bimekizumab) in adults with moderate-to-severe plaque psoriasis (PSO). In a subset of 153 patients from the second extension of BE BRIGHT, 67.7% achieved complete skin clearance (PASI100+) at five years. Among patients with PSO only at baseline, at risk of progression to psoriatic arthritis, 68.7–71.6% achieved complete skin clearance at three

Benzinga last month

UCBJY
BIMZELX® (bimekizumab-bkzx) Two-Year Data at AAD Showed Potential to Eliminate Draining Tunnels in Hidradenitis Suppurativa, and Reduction in Disease Burden

UCB, a global biopharmaceutical company, today announced two-year data from the BE HEARD^ trials for BIMZELX® (bimekizumab-bkzx) in moderate-to-severe hidradenitis suppurativa (HS). BIMZELX, the first and only medicine approved to selectively inhibit both interleukin 17A (IL-17A) and interleukin 17F (IL-17F),1 continues to demonstrate sustained disease control and durable relief from key HS symptoms, including the potential to help prevent long-term structural damage caused by draining tunnels (

PR Newswire last month

UCBJF

UCBJY
BIMZELX® (bimekizumab-bkzx) Five-Year Data at AAD 2025 Showed Sustained Skin Clearance and Long-Term Efficacy in Moderate-to-Severe Plaque Psoriasis

UCB, a global biopharmaceutical company, today announced further long-term data from the Phase 3 trials, and their open-label extensions, investigating BIMZELX® (bimekizumab-bkzx) in adults with moderate-to-severe plaque psoriasis (PSO). Dual inhibition with BIMZELX demonstrated high efficacy and sustained clinical benefits across different adult patient populations living with this common inflammatory skin condition.1-4

PR Newswire last month

UCBJF

UCBJY
UCB SA (UCBJF) (Q4 2024) Earnings Call Highlights: Strong Revenue Growth and Strategic ...

UCB SA (UCBJF) reports a robust 17% revenue increase, driven by key growth drivers and strategic market expansions, despite facing pricing pressures and increased expenses.

GuruFocus.com last month

UCBJY
On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth

UCB Full-Year Report 2024, Brussels (Belgium) – regulated information

PR Newswire last month

UCBJF

UCBJY
UCB Announces U.S. Availability of 320 mg/2 mL Single-Injection Administration Option for BIMZELX® (bimekizumab-bkzx)

UCB, a global biopharmaceutical company, announced today that a single-injection 2 mL prefilled syringe and autoinjector, each containing 320 mg of BIMZELX® (bimekizumab-bkzx) is now available. These are in addition to the currently available 1 mL device administration options, each containing 160 mg of BIMZELX.

PR Newswire 3 months ago

UCBJF

UCBJY
USNA or UCBJY: Which Is the Better Value Stock Right Now?

USNA vs. UCBJY: Which Stock Is the Better Value Option?

Zacks 3 months ago

UCBJY

USNA
UCB Presents New Data on Impact and Burden of Epilepsy at 2024 American Epilepsy Society (AES) Annual Meeting

UCB, a global biopharmaceutical company, today announced data being presented at the American Epilepsy Society (AES) Annual Meeting, taking place December 6–10 in Los Angeles, California, that focus on the impact and burden of epilepsy on people living with epilepsy and their caregivers.

PR Newswire 4 months ago

UCBJF

UCBJY
UCB presents latest scientific research in epilepsy at American Epilepsy Society (AES) Annual Meeting

UCB today announced it will present 32 abstracts from its expansive epilepsies research program at the American Epilepsy Society (AES) Annual Meeting, December 6-10, 2024 (Los Angeles, California). The data will include clinical and real-world data, plus medical research from across UCB's pipeline programs.

PR Newswire 4 months ago

UCBJF

UCBJY
Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside

On Tuesday, UCB SA (OTC:UCBJY) (OTC:UCBJF) and Biogen Inc. (NASDAQ:BIIB) presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP) for systemic lupus erythematosus. The drug candidate demonstrated significant clinical improvement in disease activity in patients with moderate-to-severe systemic lupus erythematosus (SLE). Also Read: Biogen/UCB Partnered Autoimmune Disease Candidate Hits Primary Goal In Late-Stage Study, Sets Stage Another Pivotal Trial The

Benzinga 4 months ago

BIIB

UCBJY
UCB Receives U.S. FDA Approval for BIMZELX® (bimekizumab-bkzx) as the First IL-17A and IL-17F Inhibitor for Adults with Moderate-to-Severe Hidradenitis Suppurativa

Regulated Information – Inside Information – UCB, a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved BIMZELX® (bimekizumab-bkzx) for the treatment of adults with moderate-to-severe hidradenitis suppurativa (HS).1 BIMZELX is the first and only approved medicine designed to selectively inhibit interleukin 17F (IL-17F) in addition to interleukin 17A (IL-17A).1

PR Newswire 5 months ago

UCBJF

UCBJY
Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

Dapirolizumab pegol (DZP) met its primary endpoint, demonstrating statistically and clinically significant improvement across all organ systems as measured by BICLA, an endpoint measuring disease activityA greater response was observed across multiple clinical endpoints among participants treated with DZP including 50% less severe disease flares compared to participants on standard of care aloneSystemic Lupus Erythematosus is a chronic, debilitating autoimmune disease affecting multiple organ sy

GlobeNewswire 5 months ago

UCBJF

UCBJY

BIIB
New BIMZELX® (bimekizumab-bkzx) Data at ACR Convergence 2024 Highlights UCB's Efforts to Deliver Differentiated Care for Patients with Psoriatic Arthritis and Axial Spondyloarthritis

UCB, a global biopharmaceutical company, today announced the presentation of new two-year data confirming a sustained clinical response for the IL-17A and IL-17F inhibitor BIMZELX® (bimekizumab-bkzx), in adults with active psoriatic arthritis (PsA) and those with active non-radiographic axial spondyloarthritis with objective signs of inflammation (nr-axSpA) and active ankylosing spondylitis (AS). These results are the latest from the Phase 3 studies BE OPTIMAL (PsA), BE COMPLETE (PsA), and their

PR Newswire 5 months ago

UCBJF

UCBJY
UCB showcases new data for gMG management at the 2024 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) Scientific Session

UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced that it will be presenting results from across its portfolio in generalized myasthenia gravis (gMG) at the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) annual meeting and the Myasthenia Gravis Foundation of America (MGFA) Scientific Session taking place October 15—18, 2024 at the Savannah Convention Center in Savannah, Georgia, U.S.

PR Newswire 6 months ago

UCBJF

UCBJY
UCB Announces a Head-to-Head Study Evaluating BIMZELX® (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis

UCB, a global biopharmaceutical company, today announced the start of BE BOLD, a head-to-head Phase 3b study, comparing BIMZELX® (bimekizumab-bkzx), an interleukin (IL)-17A and IL-17F inhibitor, with SKYRIZI® (risankizumab), an IL-23 inhibitor, in the treatment of adults with active psoriatic arthritis (PsA). BE BOLD is the first head-to-head study in PsA evaluating the superiority of an IL-17A and IL-17F inhibitor to an IL-23 inhibitor.

PR Newswire 6 months ago

UCBJF

UCBJY
UCB Announces Late-Breaking Two-Year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024

UCB, a global biopharmaceutical company, today announced the first presentation of two-year data from the Phase 3 studies, BE HEARD I and BE HEARD II, and their open-label extension, evaluating the efficacy and safety of BIMZELX® (bimekizumab-bkzx), an interleukin (IL)-17A and IL-17F inhibitor, in adults with moderate-to-severe hidradenitis suppurativa (HS).1 These new data are presented today as a late-breaking platform presentation at the 33rd European Academy of Dermatology and Venereology (E

PR Newswire 6 months ago

UCBJF

UCBJY

Performance Overview

Return	UCB.VI	BEL 20 (^BFX)
YTD	-24.01%	+1.19%
1-Year	+21.34%	+10.10%
3-Year	+34.91%	+2.12%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

UCB SA (UCB.VI)

UCB presents latest research across leading neurology portfolio at American Academy of Neurology (AAN) meeting 2025

UCB Convening Notice to the General Meeting of the Shareholders 2025

New data on investigational therapy for thymidine kinase 2 deficiency presented at Muscular Dystrophy Association (MDA) 2025 Conference

Epilepsia Publishes Final Analysis of Open-Label Extension Study of Long-Term Safety and Effectiveness of FINTEPLA® (fenfluramine) in Children and Adults with Dravet Syndrome

Europe-Based UCB's Bimzelx Data Reveals Sustained Skin Clearance In Inflammatory Skin Disorders

BIMZELX® (bimekizumab-bkzx) Two-Year Data at AAD Showed Potential to Eliminate Draining Tunnels in Hidradenitis Suppurativa, and Reduction in Disease Burden

BIMZELX® (bimekizumab-bkzx) Five-Year Data at AAD 2025 Showed Sustained Skin Clearance and Long-Term Efficacy in Moderate-to-Severe Plaque Psoriasis

UCB SA (UCBJF) (Q4 2024) Earnings Call Highlights: Strong Revenue Growth and Strategic ...

On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth

UCB Announces U.S. Availability of 320 mg/2 mL Single-Injection Administration Option for BIMZELX® (bimekizumab-bkzx)

USNA or UCBJY: Which Is the Better Value Stock Right Now?

UCB Presents New Data on Impact and Burden of Epilepsy at 2024 American Epilepsy Society (AES) Annual Meeting

UCB presents latest scientific research in epilepsy at American Epilepsy Society (AES) Annual Meeting

Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside

UCB Receives U.S. FDA Approval for BIMZELX® (bimekizumab-bkzx) as the First IL-17A and IL-17F Inhibitor for Adults with Moderate-to-Severe Hidradenitis Suppurativa

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

New BIMZELX® (bimekizumab-bkzx) Data at ACR Convergence 2024 Highlights UCB's Efforts to Deliver Differentiated Care for Patients with Psoriatic Arthritis and Axial Spondyloarthritis

UCB showcases new data for gMG management at the 2024 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) Scientific Session

UCB Announces a Head-to-Head Study Evaluating BIMZELX® (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis

UCB Announces Late-Breaking Two-Year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024

Performance Overview